Structure Therapeutics logo

Structure Therapeutics Share Price (NASDAQ: GPCR)

$19.32

0.18

(0.94%)

Last updated on

Check the interactive Structure Therapeutics Stock chart to analyse performance

Structure Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$18.30
    Today's High:$19.35

    Day's Volatility :5.43%

  • 52 Weeks Low:$13.22
    52 Weeks High:$45.37

    52 Weeks Volatility :70.86%

Structure Therapeutics Stock Returns

PeriodStructure Therapeutics, Inc.Index (Russel 2000)
3 Months
-11.29%
0.0%
6 Months
-13.47%
0.0%
1 Year
-49.36%
0.0%
3 Years
-25.65%
-4.1%

Structure Therapeutics, Inc. Key Stats

Check Structure Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$19.14
Open
$18.73
Today's High
$19.35
Today's Low
$18.3
Market Capitalization
$1.1B
Today's Volume
$514.6K
52 Week High
$45.37
52 Week Low
$13.22
Revenue TTM
$0.0
EBITDA
$-218.6M
Earnings Per Share (EPS)
$-3.15
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-21.14%

Stock Returns calculator for Structure Therapeutics Stock including INR - Dollar returns

The Structure Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Structure Therapeutics investment value today

Current value as on today

₹55,900

Returns

₹44,100

(-44.1%)

Returns from Structure Therapeutics Stock

₹49,384 (-49.38%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Structure Therapeutics Stock

-36%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Structure Therapeutics Stock from India on INDmoney has decreased by -36% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Structure Therapeutics Stock

Rating
Trend

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Structure Therapeutics(by analysts ranked 0 to 5 stars)

Structure Therapeutics Share Price Target

What analysts predicted

Upside of 278.24%

Target:

$73.08

Current:

$19.32

Structure Therapeutics share price target is $73.08, a slight Upside of 278.24% compared to current price of $19.32 as per analysts' prediction.

Structure Therapeutics Stock Insights

  • Price Movement

    In the last 3 months, GPCR stock has moved down by -11.2%
  • GPCR vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 119.2%

Structure Therapeutics Technicals Summary

Sell

Neutral

Buy

Structure Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Structure Therapeutics, Inc. Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Structure Therapeutics, Inc. logo
9.89%
-13.47%
-49.36%
-25.65%
-25.65%
Regeneron Pharmaceuticals, Inc. logo
3.92%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
2.49%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-15.42%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
11.08%
83.28%
75.87%
111.28%
242.25%

Structure Therapeutics Dividend announcements

  • Structure Therapeutics Earnings

    Structure Therapeutics’s price-to-earnings ratio stands at None

About Structure Therapeutics, Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Organization
Structure Therapeutics
Employees
199
CEO
Dr. Raymond C. Stevens Ph.D.
Industry
Healthcare

Key Management of Structure Therapeutics, Inc.

NameTitle
Dr. Raymond C. Stevens Ph.D.
CEO & Director
Dr. Xichen Lin Ph.D.
Chief Scientific Officer
Dr. Blai Coll M.D., Ph.D.
Chief Medical Officer
Mr. Jun S. Yoon
Co- Founder, CFO & Secretary
Dr. Yingli Ma Ph.D.
Chief Technology Officer
Mr. Tony Peng
Senior Vice President of Legal
Mr. Bob Gatmaitan
Senior Vice President of People
Dr. Hui Lei Ph.D.
Senior Vice President of Chemistry
Dr. Fang Zhang Ph.D.
Executive VP & Head of Biology
Ms. Lani Ibarra
Senior Vice President of Clinical Development Operations

Important FAQs about investing in GPCR Stock from India :

What is Structure Therapeutics share price today?

Structure Therapeutics share price today is $19.32 as on at the close of the market. Structure Therapeutics share today touched a day high of $19.35 and a low of $18.30.

What is the 52 week high and 52 week low for Structure Therapeutics share?

Structure Therapeutics share touched a 52 week high of $45.37 and a 52 week low of $13.22. Structure Therapeutics stock price today i.e. is closed at $19.32, lower by 57.42% versus the 52 week high.

How to invest in Structure Therapeutics Stock (GPCR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Structure Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Structure Therapeutics Shares that will get you 0.0776 shares as per Structure Therapeutics share price of $19.32 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Structure Therapeutics Stock (GPCR) from India?

Indian investors can start investing in Structure Therapeutics (GPCR) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Structure Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Structure Therapeutics share’s latest price of $19.32 as on August 30, 2025 at 1:29 am IST, you will get 0.5176 shares of Structure Therapeutics. Learn more about fractional shares .

What are the returns that Structure Therapeutics has given to Indian investors in the last 5 years?

Structure Therapeutics stock has given -25.65% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?